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Abstract
Introduction Cannabis-based medicines have a number of
therapeutic indications, including anti-inflammatory and
analgesic effects. The endocannabinoid receptor system,
including the cannabinoid receptor 1 (CB1) and receptor 2
(CB2) and the endocannabinoids, are implicated in a wide range
of physiological and pathophysiological processes. Pre-clinical
and clinical studies have demonstrated that cannabis-based
drugs have therapeutic potential in inflammatory diseases,
including rheumatoid arthritis (RA) and multiple sclerosis. The
aim of this study was to determine whether the key elements of
the endocannabinoid signalling system, which produces
immunosuppression and analgesia, are expressed in the synovia
of patients with osteoarthritis (OA) or RA.
Methods Thirty-two OA and 13 RA patients undergoing total
knee arthroplasty were included in this study. Clinical staging
was conducted from x-rays scored according to Kellgren-
Lawrence and Larsen scales, and synovitis of synovial biopsies
was graded. Endocannabinoid levels were quantified in synovial
fluid by liquid chromatography-mass spectrometry. The
expression of CB1 and CB2 protein and RNA in synovial biopsies
was investigated. Functional activity of these receptors was
determined with mitogen-activated protein kinase assays. To
assess the impact of OA and RA on this receptor system, levels
of endocannabinoids in the synovial fluid of patients and non-
inflamed healthy volunteers were compared. The activity of fatty
acid amide hydrolase (FAAH), the predominant catabolic
endocannabinoid enzyme, was measured in synovium.
Results CB1 and CB2 protein and RNA were present in the
synovia of OA and RA patients. Cannabinoid receptor
stimulation of fibroblast-like cells from OA and RA patients
produced a time-dependent phosphorylation of extracellular
signal-regulated kinase (ERK)-1 and ERK-2 which was
significantly blocked by the CB1 antagonist SR141716A. The
endocannabinoids anandamide (AEA) and 2-arachidonyl
glycerol (2-AG) were identified in the synovial fluid of OA and
RA patients. However, neither AEA nor 2-AG was detected in
synovial fluid from normal volunteers. FAAH was active in the
synovia of OA and RA patients and was sensitive to inhibition by
URB597 (3'-(aminocarbonyl) [1,1'-biphenyl]-3-yl)-
cyclohexylcarbamate).
Conclusion Our data predict that the cannabinoid receptor
system present in the synovium may be an important therapeutic
target for the treatment of pain and inflammation associated with
OA and RA.
2-AG = 2-arachidonyl glycerol; AEA = anandamide; CB1 = cannabinoid receptor 1; CB2 = cannabinoid receptor 2; COX = cyclooxygenase; EC = 
endocannabinoid; EGTA = ethylene glycol tetraacetic acid; ERK = extracellular signal-regulated kinase; FAAH = fatty acid amide hydrolase; IL = inter-
leukin; MAPK = mitogen-activated protein kinase; NSAID = non-steroidal anti-inflammatory drug; OA = osteoarthritis; OEA = oleoyl ethanolamide; 
PCR = polymerase chain reaction; PEA = palmitoyl ethanolamide; PTX = pertussis toxin; RA = rheumatoid arthritis; TKA = total knee arthroplasty; 
TNF = tumour necrosis factor; URB597 = 3'-(aminocarbonyl) [1,1'-biphenyl]-3-yl)-cyclohexylcarbamate.Arthritis Research & Therapy    Vol 10 No 2    Richardson et al.
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Introduction
Osteoarthritis (OA) is the most common form of arthritis affect-
ing synovial joints [1]. The aetiology of OA is poorly under-
stood, with mechanical, metabolic, and inflammatory causes.
Inflammation and angiogenesis and their possible role in dis-
ease progression and pain are increasingly being recognised
as important aetiological factors [2-5]. Rheumatoid arthritis
(RA) is a systemic, autoimmune-mediated, inflammatory arthri-
tis [6]. Although the pathogenesis remains incompletely
understood, it is characterised by severe, progressive synovi-
tis with rapid destruction of the joint. Pro-inflammatory
cytokines such as tumour necrosis factor (TNF)-α, interleukin
(IL)-1, IL-6, and chemokines such as IL-8 are abundant in RA
tissue, which is compensated to some degree by the
increased production of anti-inflammatory cytokines such as
IL-10 and transforming growth factor-β [7]. The accepted ther-
apeutic approach to RA is to use disease-modifying anti-rheu-
matic drugs at an early stage, and the recent introduction of
cytokine inhibitor drugs has increased the effectiveness of
treatment considerably. However, an effective remission-
inducing drug has yet to be discovered, and the vast majority
of RA patients are dependent on lifelong treatment in order to
suppress joint damage and functional impairment [6]. There
are no proven disease-modifying OA drugs, and current non-
steroidal anti-inflammatory drug (NSAID) treatments do not
always provide adequate pain relief and have detrimental side
effects. Thus, there is a strong rationale for the development of
novel drug treatments for arthritis. This can be achieved only
by an improved mechanistic understanding of the functional
cellular changes associated with this disease.
The cannabinoid receptor system has been implicated in a
wide range of physiological and pathophysiological processes
[8]. Recent pre-clinical and clinical studies have demonstrated
that cannabis-based drugs have therapeutic potential in
inflammatory diseases, including RA and multiple sclerosis [9].
Animal studies have demonstrated that activation of cannabi-
noid receptors attenuates inflammation and nociceptive
processing in models of cutaneous and joint inflammation [10-
14]. The cannabis-based medicine Sativex (GW Pharmaceuti-
cals plc, Salisbury, Wiltshire, UK) has been reported to pro-
duce a significant analgesic effect and to suppress disease
activity in patients with RA [15].
Two cannabinoid receptors (CB1 and CB2), both of which are
inhibitory G protein-coupled receptors, have been cloned [8].
CB1  receptors are expressed predominantly by peripheral
nerves, spinal cord, and the nervous system as well as periph-
eral immune cells [16]. CB2 receptors are expressed mainly in
peripheral tissue, in particular by immune cells [17]. Activation
of CB1 receptors is associated predominantly with a dampen-
ing down of neuronal excitability, whereas activation of CB2
receptors is associated with decreases in immune cell func-
tion, including attenuated cytokine release [9,17]. A number of
endocannabinoids with activity at the CB1 and CB2 cannabi-
noid receptors, including N-arachidonyl ethanolamide (anan-
damide, AEA) and 2-arachidonyl glycerol (2-AG), have been
identified [18,19]. Other structurally related endogenous fatty
acid compounds such as oleoyl ethanolamide (OEA) and
palmitoyl ethanolamide (PEA) have been identified in biologi-
cal tissues. These compounds do not bind to cannabinoid
receptors but might be involved in facilitating the actions of
directly acting endocannabinoids and thus are commonly
termed 'entourage' compounds due to their ability to modulate
the endocannabinoid system [20,21]. The endocannabinoids
and PEA are synthesised on demand, and AEA, PEA, and
OEA are metabolised predominantly by fatty acid amide hydro-
lase (FAAH) [22,23].
Although the therapeutic benefits of Sativex in RA patients are
significant, the mechanisms mediating these effects are
unclear. Indeed, the impact of arthritis on the endocannabinoid
receptor system, both in terms of receptor expression and lev-
els of endocannabinoids and entourage compounds, is
unknown. The endocannabinoid system appears to regulate
bone mass by signalling via peripheral CB2 receptors in both
osteoblasts and osteoclasts [24]. In a separate study, CB1
knockout mice had significantly increased bone mineral den-
sity compared with wild-type mice and were protected from
ovariectomy-induced bone loss and CB1- and CB2-selective
cannabinoid receptor antagonists inhibited osteoclastogene-
sis in vivo [25]. Thus, the role of the cannabinoid receptor sys-
tem in bone remodelling and aspects of pathological
conditions such as periarticular bony erosions in RA and
subchondral bony sclerosis in OA remains unclear.
Several NSAIDs, including ibuprofen, ketorolac, indometacin,
and niflumic acid, which act via the inhibition of cyclooxygen-
ase (COX), have been shown to inhibit FAAH [26,27]. This
suggests that current treatment of inflammatory pain in OA
and RA patients using NSAIDs may be targeting endocannab-
inoid metabolism in addition to arachidonic acid metabolism.
These interactions may be of great clinical importance in terms
of multiple-target drug development as synergistic actions of
the COX-2 inhibitor rofecoxib and the endocannabinoid AEA
have been observed in an animal model of pain [28].
The aim of the present study was to provide evidence of a role
for the cannabinoid receptor system in OA and RA. Here, we
report the presence of an active endocannabinoid system,
including endocannabinoids, entourage compounds, CB1 and
CB2 receptors, and FAAH, in the knee synovia of patients with
end-stage OA and RA.
Materials and methods
Patient information and tissue collection
The Nottingham Regional Ethical Committee approved the
study, and after informed consent synovial biopsies and fluid
were sampled from patients undergoing total kneeAvailable online http://arthritis-research.com/content/10/2/R43
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arthroplasty (TKA). All x-rays were scored according to Kell-
gren and Lawrence [29] (OA) and Larsen [30] (RA) scales.
The synovial fluid and biopsies were collected under tourni-
quet control at the onset of the TKA from 32 OA and 13 RA
patients. The synovial fluid samples were centrifuged at 1,000
g for 40 minutes at 4°C, and the supernatants were retained
for analysis. Samples of synovial fluid from non-inflamed nor-
mal volunteers (n = 6) were kindly provided by Michael
Doherty, Academic Rheumatology, Nottingham University
Hospitals.
Synovium histology and analysis
Synovial biopsies designated for histological analysis were
fixed in 10% formal saline (Sigma-Aldrich, St. Louis, MO,
USA), processed into paraffin wax, and stained with Weigert's
haematoxylin and eosin. Each biopsy was assigned to one of
four categories: 0 = normal: synovial intima less than four cells
thick with sparse cellular distribution and few or no inflamma-
tory cells; 1 = mild inflammation: synovial intima three to five
cells thick with slight increase in cellularity and with few inflam-
matory cells; 2 = moderate inflammation: synovial intima four
to six cells thick, with dense cellularity and inflammatory cells,
may exhibit as small lymphoid aggregates; and 3 = severe
inflammation: synovial intima five to seven or more cells thick,
dense cellularity with inflammatory cells, containing many or
large perivascular lymphoid aggregates [3]. Representative
micrographs of this grading system are presented in Figure 1.
Quantification of inflammatory cytokines in synovial 
fluid
Cytokine profiles in synovial fluid were determined using a
BD™ cytometric bead array (BD Biosciences, San Jose, CA,
USA), which quantified IL-8, IL-1β, IL-6, IL-10, TNF, and IL-
12p70. Analysis was performed using a Beckman Coulter
Epics™ Altra® flow cytometer (Beckman Coulter, Fullerton,
CA, USA) according to the manufacturer's protocol for meas-
urements in serum or plasma.
Measurement of endocannabinoids
A lipid extraction method was used as previously described
[31]. In brief, tissue or fluid was homogenised in an ethyl ace-
tate/hexane mixture with internal standards (0.42 nmol AEA-
d8, 1.5 nmol 2-AG-d8, and 0.2 nmol heptadecanoyl ethanola-
mide) and left in extraction solvent for 2 hours with intermittent
mixing. Repeated centrifugation and supernatant collection
were then undertaken, followed by purification of samples by
solid-phase extraction.
Simultaneous measurement of AEA, 2-AG, OEA, and PEA
was then performed using liquid chromatography-tandem
mass spectrometry. A triple quadrupole Quattro Ultima mass
spectrometer (Waters Ltd, Manchester, UK) was used in elec-
trospray-positive mode and coupled to an Agilent 1100 LC
system (Agilent Technologies, Böblingen, Germany) for analy-
sis. Analytes were chromatographically separated on a HyPu-
rity Advance C8 column (Fisher Scientific UK., Loughborough,
UK) with gradient elution. Individual compounds were then
identified and quantified with multiple reaction monitoring,
using (m/z [mass-to-charge] ratios of specific precursor and
product ions) on the mass spectrometer.
Figure 1
Representative haematoxylin and eosin micrographs of synovium biop- sies taken at osteoarthritis or rheumatoid arthritis total knee arthroplasty Representative haematoxylin and eosin micrographs of synovium biop-
sies taken at osteoarthritis or rheumatoid arthritis total knee arthro-
plasty. (a-c) Osteoarthritis: (a) category 1 (least inflamed), (b) category 
2, and (c) category 3 (most inflamed). I, synovium intima; L, lymphoid 
body; SV, small vessel; V, villus. (d) Rheumatoid arthritis, category 3. 
Each biopsy was assigned to one of four categories: 0 = normal: syno-
vial intima less than four cells thick, sparse cellular distribution, with few 
or no inflammatory cells (not shown as normal synovial fluid samples 
were not accompanied by synovium biopsies); 1 = mild inflammation: 
synovial intima three to five cells thick, slight increase in cellularity with 
few inflammatory cells; 2 = moderate inflammation: synovial intima four 
to six cells thick, dense cellularity with inflammatory cells, may exhibit as 
small lymphoid aggregates; 3 = severe inflammation: synovial intima 
five to seven or more cells thick, dense cellularity with inflammatory 
cells, containing many or large perivascular lymphoid aggregates. Bar = 
100 μm.Arthritis Research & Therapy    Vol 10 No 2    Richardson et al.
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Western blotting for measurement of cannabinoid 
receptor expression
Human synovium samples were homogenised in lysis buffer
(20 mM Tris, 1 mM ethylene glycol tetraacetic acid [EGTA],
320 mM sucrose, 0.1% Triton X100, 1 mM sodium fluoride,
and 10 mM β-glycerophosphate) containing a protease inhib-
itor cocktail (Roche Applied Sciences, Burgess Hill, UK).
Homogenates were centrifuged at 5,000 g for 10 minutes at
4°C and the resulting supernatants were collected. Estimation
of protein content was carried out using the Lowry method
[32]. Aliquots of the homogenate supernatant were diluted in
Laemmli sample buffer, and proteins were separated using
10% SDS-PAGE and blotted onto nitrocellulose membranes.
Anti-cannabinoid receptor 1 (Calbiochem, now part of EMD
Biosciences, Inc., San Diego, CA, USA), anti-cannabinoid
receptor 2 (Cayman Chemical Company, Ann Arbor, MI,
USA), or anti-β-actin antibody (Sigma-Aldrich) was incubated
overnight at 4°C with nitrocellulose membranes and visualisa-
tion using horseradish peroxidase-conjugated secondary anti-
bodies (1:2,000 dilution; Dako Denmark A/S, Glostrup,
Denmark), enhanced chemiluminescence detection (Amer-
sham Biosciences, now part of GE Healthcare, Little Chalfont,
Buckinghamshire, UK), and autoradiography. Data were quan-
tified using a Bio-Rad GS 710 imaging densitometer (Bio-Rad
Laboratories, Inc., Hercules, CA, USA).
Fatty acid amide hydrolase activity assay
Tissues were homogenised (50 mM Tris-HCl, 1 mM EDTA
[ethylenediaminetetraacetic acid], 3 mM MgCl2, pH 7.4) and
centrifuged at 500 g for 5 minutes at 4°C, and the supernatant
was subsequently centrifuged for 30 minutes at 35,000 g at
4°C. The pellet obtained was re-suspended in Tris-HCl buffer,
and protein content was determined by the method of Lowry.
The FAAH activity of each sample was measured by monitor-
ing the release of [3H]-ethanolamine after incubation of
homogenate with radiolabelled AEA ([3H]-AEA). Protein con-
tents per assay were chosen on the basis of preliminary exper-
iments using some of the samples to establish optimal
conditions (~88 μg/mL). Homogenised tissue in assay buffer
(116 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 25 mM HEPES,
1 mM NaH2PO4, 0.8 mM MgSO4, pH 7.0) was incubated at
37°C with 40 μM [3H]-AEA (American Radiolabeled Chemi-
cals, Inc., St. Louis, MO, USA) in the presence of 1 mg/mL
fatty acid-free bovine serum albumin (200 μL total assay vol-
ume), and the reaction was stopped by the addition of 0.4 mL
activated charcoal (4% wt/vol in 0.5 M HCl) [33,34]. A sample
without homogenate was processed to determine the extent of
non-enzymatic [3H]-AEA hydrolysis. The samples were vor-
texed and left to sediment for 30 minutes before centrifugation
at 11,000 g for 5 minutes to pellet the charcoal and homoge-
nate protein with un-hydrolysed [3H]-AEA. A 200-μL aliquot of
the supernatant was counted for tritium content by liquid scin-
tillation spectroscopy. For obtaining standards, an aliquot of
the homogenate was incubated without [3H]-AEA and
stopped with charcoal as for other samples. After centrifuga-
tion, 190 μL of supernatant was added into scintillation vials
with 40 μM [3H]-AEA (equivalent to 2 nmol [3H]-AEA/mL) and
activity was determined as before.
Preparation and culture of human synovial fibroblast 
cells
Human synovial samples from both OA and RA patients were
chopped and finely digested for 2 hours at 37°C with 2 mg/
mL collagenase type H (Sigma-Aldrich) in Dulbecco's modi-
fied Eagle's medium (Sigma-Aldrich) supplemented with 10%
foetal calf serum (PAA Laboratories Ltd, Yeovil, UK, Pasching,
Austria), 2 mM L-glutamine (Sigma-Aldrich), 50 U/mL penicil-
lin, and 50 μg/mL streptomycin and fungizone (Sigma-
Aldrich). Samples were occasionally agitated to aid digestion.
At the end of the digest, the samples were pipetted up and
down to disrupt the tissue and passed through a 100-μm cell
strainer (BD Falcon, a trademark of BD Biosciences). The cell
suspension was centrifuged at 500 g for 5 minutes at room
temperature, and the pellet was re-suspended in complete
media, plated into flasks, and allowed to become adherent.
Media was replaced the following day to remove any non-
adherent cells. Adherent cells were cultured and used
between passages 3 and 12.
Immunoblotting of synovial fibroblast for mitogen-
activated protein kinase activation
To analyse mitogen-activated protein kinase (MAPK) activa-
tion, synovial fibroblast-like cells were stimulated with the
CB1/CB2 receptor agonist HU210 (1 μM) in the presence and
absence of a 20-hour pre-incubation with pertussis toxin (PTX)
for 5, 10, 20, and 40 minutes before analysis of MAPK phos-
phorylation (described below) to determine a maximum time-
dependent effect of HU210 stimulation on MAPK phosphor-
ylation compared with basal, unstimulated levels. In subse-
quent experiments, synovial fibroblast-like cells were
stimulated with HU210 (0.1 μM) in the presence and absence
of the CB1 antagonist SR141716A (1 μM) or CB2 antagonist
SR144528 (1 μM). Cells were washed with phosphate-buff-
ered saline (Sigma-Aldrich) and lysed (20 mM Tris, 1 mM
EGTA, 320 m sucrose, 0.1% Triton X100, 1 mM sodium fluo-
ride, and 80 mM β-glycerophosphate containing protease
inhibitor cocktail). After removal of a sample for a protein
assay, the homogenate was diluted in Laemmli sample buffer
and heated at 95°C for 5 minutes. Equal amounts of protein
from each sample were separated on 10% SDS-PAGE gels
and then transferred onto nitrocellulose membranes for West-
ern blotting. Nitrocellulose blots were incubated overnight at
4°C with an antibody that recognises the double-phosphor-
ylated (activated) forms of both isoforms of extracellular signal-
regulated kinase (ERK) (p44 ERK1 MAPK and p42 ERK2
MAPK) and p38 MAPK (New England Biolabs, Inc., Ipswich,
MA, USA). Proteins were subsequently visualised using the
ECL system (Amersham Life Sciences, now part of GE Health-
care). Blots were then stripped of antibodies using RestoreAvailable online http://arthritis-research.com/content/10/2/R43
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Western Blot Stripping Buffer (Pierce, Rockford, IL, USA)
according to the manufacturer's instructions. These blots were
subsequently re-probed with an antibody against total ERK
and p38 (New England Biolabs, Inc.). Bands were visualised
as before. Data were quantified using the Bio-Rad GS 710
imaging densitometer and represented as a percentage of the
unstimulated control.
Reverse transcription-polymerase chain reaction for CB1 
and CB2 receptors
Total RNA was isolated from cultured human synovial-like
fibroblasts using TRiPure Isolation reagent (Roche Applied
Sciences, Burgess Hill, UK) according to the manufacturer's
instructions. As the open reading frame for CB1 and CB2 can-
nabinoid receptors for humans contains a single exon, the
RNA used was treated with recombinant RNase-free DNase-
1 (Roche) to remove any genomic DNA contamination and
was purified using a standard phenol-chloroform extraction
methodology. RNA was reverse-transcribed into cDNA using
the Transcriptor first-strand cDNA synthesis kit (Roche
Applied Sciences, Burgess Hill, UK) according to the manu-
facturer's instructions. Amplification of CB1 and CB2 cannabi-
noid receptor cDNA was achieved by using 'touchdown'
polymerase chain reaction (PCR) with a progressive decrease
in annealing temperatures from 60°C until touchdown at 55°C
[35]. Primers were designed using the Primer Express soft-
ware package version 3.0 (Applied Biosystems, Foster City,
CA, USA). Using bioinformatics, the specificities of all primers
were confirmed to the desired mRNA of human samples. Prim-
ers used were as follows: CB1 forward: 5'-CTGAACTCCAC-
CGTGAACC-3' and reverse: 5'-GTGCTCTTGATGCAGCT-
5' and CB2 forward: 5'-CATCTATGCTCTACGGAGTGGA-
GAG-3' and reverse: 5'-TTGAGTTGTTTAAATTGGGAA-
GAGG-3' (MWG-Biotech AG, Ebersberg, Germany). The
amplified products were separated on a 1.8% low-melting
agarose gel (Invitrogen Corporation, Carlsbad, CA, USA)
stained with ethidium bromide and documented using Gene-
Snap imaging software (Syngene, Cambridge, UK).
Data analysis
Statistical comparisons of levels of cytokines between normal,
OA, and RA samples were performed with a non-parametric
Kruskal-Wallis test. Comparisons of endocannabinoid (EC)
levels between normal, OA, and RA samples were performed
with a non-parametric Mann-Whitney test. Comparison of
FAAH activity between OA and RA synovial tissue was per-
formed using unpaired Student t tests. Comparisons between
drug treatment groups in cultured fibroblast-like cell immuno-
blots were performed using one-way analysis of variance fol-
lowed by Bonferroni multiple comparison post hoc test. A P
value of less than 0.05 was considered a significant
difference.
Results
Patient information
All patients had a Kellgren-Lawrence or Larsen radiological
score of greater than or equal to 3. The study included 14 male
and 18 female OA patients and 1 male and 12 female RA
patients. The patients had a similar mean age, and information
on drug history prior to TKA is summarised in Table 1. Patients
were told to stop taking aspirin and all cytokine inhibitors 10
to 14 days prior to surgery.
Histology of synovial biopsies and levels of cytokines
Haematoxylin and eosin histology was performed on 26 of the
OA and 9 of the RA synovial biopsies to assess the degree of
inflammation (Figure 1). None of the OA synovia was
characterised as having a normal histological appearance, 4
exhibited mild (score = 1), 12 moderate (score = 2), and 10
severe (score = 3) synovial inflammation. In the case of the RA
synovial biopsies, one sample had become fibrotic and devoid
of a cellular component and therefore could not be scored. Six
of the RA biopsies were described as exhibiting severe syno-
vitis (score = 3) and two as having moderate inflammation
(score = 2).
In addition to assessing the degree of degeneration of the syn-
ovium of the patients included in this study, levels of inflamma-
Table 1
Summary of patient histories of osteoarthritis and rheumatoid arthritis patients included in the study
Osteoarthritis Rheumatoid arthritis
Gender (number) Female (18) Male (14) Female (12) Male (1)
Mean age ± standard deviation, years 72 ± 7 70 ± 8 61 ± 11 64
NSAIDs, number (percentage) 8 (44%) 7 (50%) 8 (67%) 0
Paracetamol, number (percentage) 9 (50%) 7 (50%) 9 (75%) 1 (100%)
Corticosteroid, number (percentage) 0 0 8 (67%) 0
NSAIDs, paracetamol or corticosteroid, number (percentage) 12 (67%) 9 (64%) 12 (100%) 1 (100%)
Anti-cytokine therapy, number (percentage) 0 0 1 (8%) 1 (100%)
NSAID, non-steroidal anti-inflammatory drug.Arthritis Research & Therapy    Vol 10 No 2    Richardson et al.
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tory cytokines in the synovial fluid of these patients were
quantified. Levels of cytokines (IL-8, IL-1β, IL-6, IL-10, TNF,
and IL-12) were assayed in 17 of the OA synovial fluid sam-
ples, 6 RA samples, and 6 samples from patients with no clin-
ical symptoms (described as normal). In general, levels of
cytokines were higher in the synovial samples from RA
patients compared with OA and normal samples (Figure 2)
and there was a large spread of data in the RA group. Statis-
tical comparison between levels of cytokines in the three
groups revealed that levels of IL-6 were significantly higher in
the RA (P < 0.01) and OA (P < 0.05) samples compared with
normal synovial fluid samples (Figure 2). There were no signif-
icant differences between levels of the other cytokines for the
three groups.
Cannabinoid receptors are expressed in human synovial 
tissue from osteoarthritis and rheumatoid arthritis 
patients
The expression of cannabinoid receptors in human synovial tis-
sue obtained from OA and RA patients was assessed. Immu-
noblotting for CB1 receptor protein in human synovial tissue
detected a major band at about 63 kDa, consistent with previ-
ous reports (Figure 3a) [36-39]. The expression of CB2 recep-
Figure 2
Comparison of levels of cytokines in synovial fluid from patients with rheumatoid arthritis (RA) (n = 6) and osteoarthritis (OA) (n = 17) and from non- inflamed normal volunteers (normal) (n = 6) Comparison of levels of cytokines in synovial fluid from patients with rheumatoid arthritis (RA) (n = 6) and osteoarthritis (OA) (n = 17) and from non-
inflamed normal volunteers (normal) (n = 6). Levels of interleukin (IL)-6 were significantly higher in RA and OA groups (P < 0.05 for both) compared 
with the normal group (Kruskal-Wallis non-parametric test and Dunn multiple comparison post hoc test). Lines represent median values. TNF, tumour 
necrosis factor.Available online http://arthritis-research.com/content/10/2/R43
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tor protein was also detected in synovial tissue by Western
blotting. Three bands probably representing different glycoso-
lation states, at about 40, 55, and 60 kDa (Figure 3a), were
detected in a pattern similar to that previously reported for
spleen, brainstem, and cerebellum [40]. Processing immuno-
blots without primary antibody or pre-absorbing with antigenic
peptide abolished the identified bands (data not shown).
CHO-K1 cells recombinantly expressing either the human
CB2 receptor or human CB1 receptor protein were used as a
positive control. There were no significant differences
between levels of expression of CB1 and CB2 receptor pro-
teins in synovial tissue from OA (n = 4) and RA (n = 4)
patients. To further strengthen the evidence for CB1 and CB2
receptor expression in synovial tissue from OA and RA
patients, touchdown PCR was used to detect RNA for CB1
and CB2 receptors. CB1 and CB2 RNA was observed in all
human synovial fibroblast-like synovial cells analysed with a
product size of 201 base pairs, as predicted (Figure 3b). The
human neuroblastoma cell line SHSY-5Y, which endog-
enously expresses CB1  cannabinoid receptors [41], and
CHO-K1 cells recombinantly expressing human CB2 cannabi-
noid receptors were used as positive controls. The lack of
amplification in non-template controls and in the absence of
reverse transcriptase indicates the absence of any contamina-
tion or amplification of genomic DNA (data not shown).
Determination of fatty acid amide hydrolase activity in 
human synovial tissue
Membrane fragments prepared from synovial tissue were
assayed for determining FAAH activity. A rat liver membrane
preparation, previously demonstrated to be rich in FAAH activ-
ity, was used as a positive control [42]. The selective FAAH
inhibitor URB597 (3'-(aminocarbonyl) [1,1'-biphenyl]-3-yl)-
cyclohexylcarbamate) (1 μM) virtually abolished activity in this
tissue (Table 2). Although FAAH activity was much lower in
synovium, activity was measurable in tissue from OA and RA
patients (Table 2). There were no significant differences in
FAAH activity between synovial tissue from OA and RA
patients. Incubation of samples with URB597 (1 μM) also
markedly reduced FAAH activity (Table 2) in the synovium
Figure 3
Expression of cannabinoid receptor 1 (CB1) (a) and cannabinoid receptor 2 (CB2) (b) receptor protein in synovial tissue of patients with osteoarthri- tis (OA) (lanes 2 to 5) or rheumatoid arthritis (RA) (lanes 6 to 8) detected by Western blotting and quantified by densitometry Expression of cannabinoid receptor 1 (CB1) (a) and cannabinoid receptor 2 (CB2) (b) receptor protein in synovial tissue of patients with osteoarthri-
tis (OA) (lanes 2 to 5) or rheumatoid arthritis (RA) (lanes 6 to 8) detected by Western blotting and quantified by densitometry. CHO-K1 cells recom-
binantly expressing either CB1 or CB2 receptor were used as a positive control (lane 1). Receptor expression was calculated as a percentage of 
expression of the internal control, β-actin. Data are presented as mean ± standard error of the mean of the expression of CB1 and CB2 protein in four 
OA and four RA patients, assessed in three separate experiments. Expression of CB1 (c) and CB2 (d) receptor RNA in fibroblast-like synovial cells 
derived from tissue of patients with OA or RA detected by 'touchdown' polymerase chain reaction. A human neuroblastoma cell line (SH-SY5Y) 
endogenously expressing CB1 cannabinoid receptor and CHO-K1 cells recombinantly expressing CB2 receptor were used as positive controls, 
respectively. bp, base pairs.Arthritis Research & Therapy    Vol 10 No 2    Richardson et al.
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[43].
Endocannabinoid levels in synovium tissue and synovial 
fluid in normal, osteoarthritis, and rheumatoid arthritis 
samples
The synovial tissue from OA and RA patients was used to
measure endocannabinoid and entourage compounds. AEA,
2-AG, OEA, and PEA were detected and quantified in all sam-
ples analysed (Figure 4). Comparison of OA and RA tissue
showed no significant differences in levels of AEA, 2-AG,
OEA, or PEA.
Endocannabinoids and entourage compounds were meas-
ured in control synovial fluid from normal volunteers with no
joint symptoms as well as in synovial fluid from OA and RA
patients (Figure 5). AEA and 2-AG were not detected in the
normal synovial fluid samples (below the lower limit of quanti-
fication of 0.3 pmol/mL). By contrast, significant levels of OEA
and high levels of PEA were detected in these normal samples
Table 2
Fatty acid amide hydrolase (FAAH) activity in synovial tissue from osteoarthritis (n = 5) and rheumatoid arthritis (n = 4) patients
FAAH activity (pmol/minute/mg protein)
Tissue Control + URB597
Osteoarthritis synovium 2.8 ± 0.46 Undetectable
Rheumatoid arthritis synovium 1.6 ± 0.42 Undetectable
Rat liver 988 ± 84 1.28 ± 0.51
FAAH activity was measured by monitoring the release of [3H]-ethanolamine after incubation of homogenates with [3H]-anandamide. Each sample 
was processed in three separate experiments. Data are presented as mean ± standard error of the mean. URB597, 3'-(aminocarbonyl) [1,1'-
biphenyl]-3-yl)-cyclohexylcarbamate.
Figure 4
Levels of the endocannabinoids anandamide (AEA), 2-arachidonyl glycerol (2-AG), palmitoyl ethanolamide (PEA), and oleoyl ethanolamide (OEA) in  the synovia of patients with either osteoarthritis (OA) (n = 14) or rheumatoid arthritis (RA) (n = 6) Levels of the endocannabinoids anandamide (AEA), 2-arachidonyl glycerol (2-AG), palmitoyl ethanolamide (PEA), and oleoyl ethanolamide (OEA) in 
the synovia of patients with either osteoarthritis (OA) (n = 14) or rheumatoid arthritis (RA) (n = 6). Data were analysed using the non-parametric 
Mann-Whitney test and are expressed as picomoles per gram.Available online http://arthritis-research.com/content/10/2/R43
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(Figure 5). Consistent with synovial tissue, AEA, 2-AG, OEA,
and PEA were detected in synovial fluid samples taken from
the same OA and RA patients (Figure 5). In contrast to the
high levels of PEA in synovial fluid samples of normal volun-
teers, levels were greatly reduced in OA and RA samples. In
addition, there was a trend toward a reduction in levels of OEA
in OA and RA samples compared with control synovial fluid
samples, although this did not reach statistical significance.
Comparison of levels of endocannabinoid and entourage com-
pounds in the synovial fluid versus synovia of OA and RA
patients revealed that, generally, levels were lower (per millili-
tre of fluid) in the fluid compared with the synovial tissue (per
gram of tissue).
Effects of HU-210 on ERK1, ERK2, and p38 MAPK 
activation in fibroblast-like cells
Levels of phosphorylated and total ERK1, ERK2 (p44 and
p42, respectively), and p38 MAPK were measured in fibrob-
last-like cells from OA and RA patients, derived from the syn-
ovial tissue, by Western blotting. Given the comparable levels
of expression of CB1 and CB2 receptor protein in OA and RA
samples, we combined RA and OA cells to maximise cell yield
for these pharmacological experiments. The non-selective can-
nabinoid receptor agonist HU210 (1 μM) produced a time-
dependent phosphorylation of ERK1, ERK2, and p38 MAPK,
indicating an increase in ERK and p38 activity which peaked
at 10 minutes after stimulation (Figure 6). Levels of total ERK1,
ERK2, and p38 were unaffected by HU210 (data not shown).
Pre-treatment of fibroblast-like cells with PTX, which ADP-
ribosylates and inactivates Gαi/o, decreased HU210-induced
phosphorylation. The effect of PTX was significant for p38
activation after a 10-minute stimulation with HU210 (P  <
0.05); although PTX showed a tendency to decrease HU210-
induced activation of ERK1 and ERK2, significance was not
reached. These data suggest a role for a Gαi/o-coupled recep-
tor mediating the effects of HU210 on ERK1, ERK2, and p38
activation (Figure 6). To further investigate the role of the can-
nabinoid receptors in mediating the effects of HU210 on
phosphorylation of ERK1, ERK2, and p38 MAPK, the potential
ability of the CB1 and CB2 receptor antagonists SR141716A
and SR144528 to block the effects of HU210 (0.1 μM) was
studied. The CB1 receptor antagonist SR141716A (1 μM) sig-
nificantly attenuated HU210 (0.1 μM)-induced phosphoryla-
tion of ERK1 and ERK2 in fibroblast-like cells (Figure 7).
Figure 5
Levels of the endocannabinoids anandamide (AEA), 2-arachidonyl glycerol (2-AG), palmitoyl ethanolamide (PEA), and oleoyl ethanolamide (OEA) in  synovial fluid of non-inflamed normal volunteers (control) (n = 6) and of patients with osteoarthritis (OA) (n = 14) and rheumatoid arthritis (RA) (n =  5) Levels of the endocannabinoids anandamide (AEA), 2-arachidonyl glycerol (2-AG), palmitoyl ethanolamide (PEA), and oleoyl ethanolamide (OEA) in 
synovial fluid of non-inflamed normal volunteers (control) (n = 6) and of patients with osteoarthritis (OA) (n = 14) and rheumatoid arthritis (RA) (n = 
5). Data were analysed using the non-parametric Mann-Whitney test and are expressed as picomoles per millilitre. **P < 0.01, ***P < 0.005 com-
pared with control values. á P < 0.05 compared with OA values. ND, not detected below a limit of detection of 0.3 pmol/mL.Arthritis Research & Therapy    Vol 10 No 2    Richardson et al.
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Although the CB2 receptor antagonist SR144528 (1 μM)
tended to attenuate HU210 (0.1 μM)-induced phosphoryla-
tion of ERK1 and ERK2 in fibroblast-like cells, significance
was not reached (Figure 7). Levels of total ERK1 and ERK2
were unaffected by the drug treatments (Figure 7a). HU210-
induced phosphorylation of p38 MAPK was not significantly
attenuated by the CB1 or CB2 receptor antagonist (data not
shown). Overall, these pharmacological studies provide
strong support for functionally coupled cannabinoid receptors
in the fibroblast-like cells derived from synovia from OA and
RA patients.
Discussion
The novel finding of the present study is the identification of
the key components of the cannabinoid receptor system in the
knee synovia of patients with end-stage OA and RA. We have
demonstrated, for the first time, the presence of cannabinoid
CB1 and CB2 receptor message and protein. The functional
relevance of the presence of these receptors has been con-
firmed by pharmacological studies demonstrating cannabinoid
agonist-induced phosphorylation of the downstream signalling
Figure 6
HU210 (1 μM) induces a time-dependent increase in (a) p44 (ERK1),  (b) p42 (ERK2), and (c) p38 mitogen-activated protein kinase (MAPK)  phosphorylation (filled bars) in fibroblast-like cells derived from the syn- ovia of patients with rheumatoid arthritis or osteoarthritis compared  with basal levels HU210 (1 μM) induces a time-dependent increase in (a) p44 (ERK1), 
(b) p42 (ERK2), and (c) p38 mitogen-activated protein kinase (MAPK) 
phosphorylation (filled bars) in fibroblast-like cells derived from the syn-
ovia of patients with rheumatoid arthritis or osteoarthritis compared 
with basal levels. Pre-incubation (20 hours) of cells with pertussis toxin 
(PTX) attenuated HU210-induced phosphorylation. Data are presented 
as mean percentage of unstimulated basal MAPK phosphorylation lev-
els ± standard error of the mean (n = 3 synovia). Comparisons 
between groups were made using one-way analysis of variance. *P < 
0.05, **P < 0.01 versus basal levels, φ P < 0.05 versus corresponding 
PTX-stimulated time point. ERK, extracellular signal-regulated kinase.
Figure 7
Pre-incubation of fibroblast-like cells with the cannabinoid receptor 1  (CB1) antagonist SR141716A (1 μM) for 10 minutes prior to exposure  to HU210 (for a further 10 minutes, 0.1 μM) significantly blocked  HU210-induced phosphorylation of p44 (ERK1) and p42 (ERK2) Pre-incubation of fibroblast-like cells with the cannabinoid receptor 1 
(CB1) antagonist SR141716A (1 μM) for 10 minutes prior to exposure 
to HU210 (for a further 10 minutes, 0.1 μM) significantly blocked 
HU210-induced phosphorylation of p44 (ERK1) and p42 (ERK2). The 
cannabinoid receptor 2 (CB2) antagonist SR144528 (1 μM) did not 
significantly alter HU210-induced phosphorylation of p44 (ERK1) and 
p42 (ERK2). Data are expressed as (a) immunoblots with levels of 
phosphorylated mitogen-activated protein kinase (MAPK) in the top 
band and total loading of protein below and as (b) mean percentage of 
the unstimulated basal levels of MAPK phosphorylation ± standard 
error of the mean (n = 3 synovia). Comparison between drug treatment 
groups was carried out using one-way analysis of variance. **P < 0.05 
versus HU210. ERK, extracellular signal-regulated kinase.Available online http://arthritis-research.com/content/10/2/R43
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targets (ERK1 and ERK2) in fibroblast-like cells derived from
OA and RA patients. The endocannabinoids, plus associated
entourage compounds and FAAH activity, were present in the
synovia of both OA and RA patients. In addition, we have dem-
onstrated that AEA and 2-AG are also present in the synovial
fluid of OA and RA patients but are not detectable in synovial
fluid taken from volunteers with no joint symptoms. Our data
provide evidence for a functional endocannabinoid receptor
system in OA and RA patients.
All synovia used in the present study were collected from RA
and OA patients with end-stage disease undergoing TKA for
severe pain. Histological analysis verified that the synovia were
not normal. Both the OA and RA synovia exhibited either mod-
erate or severe inflammation. Moderate or severe synovitis was
classified as the intima layer being more than four cells deep,
plus dense cellularity of subintimal tissue due to increased
numbers of fibroblastic cells and inflammatory cells, including
lymphoid aggregates [3,44,45]. In general, the number of lym-
phoid aggregates and cell depth of the synovial intima are
greater, or more extensive, in RA than OA synovium [46,47].
All of the RA and OA patients whose samples were used in
this study exhibited severe disease and there were no signifi-
cant differences between levels of cytokines in RA and OA
samples studied. Levels of IL-6, however, were significantly
higher in OA and RA samples compared with volunteers with
no joint symptoms. IL-6 is an important driver of inflammation
in RA [48] and all of the synovia, whether RA or OA, were
inflamed in our study. IL-6 is also implicated in the induction of
osteoclast differentiation and bone resorption [49], and all of
our patients had bone-on-bone changes somewhere within
their arthritic knees, reflecting the severity of end-stage
disease requiring joint replacement surgery. Reported levels of
IL-6 [50,51] and IL-8 [51,52] are in keeping with earlier
reports in OA and RA.
Although it may be expected that levels of pro-inflammatory
cytokines would be higher in RA samples, all of the patients
had taken anti-arthritis medicines, which could affect levels of
cytokines and possibly endocannabinoids. As a result of the
different requirements for sample preparation and the amount
of synovia available, not all of the synovia could be used for all
of the experimental studies. Given the wide range of cytokine
levels present in OA and RA samples, we have studied the
cannabinoid receptor system in groups of OA and RA samples
which represent a cross-section of the population in terms of
levels of cytokines, ensuring that our data were not subject to
bias. Due to difficulties in recruiting male RA subjects, only one
was included in the study, but similarities between the extent
of disease in the male and female subjects and the lack of sig-
nificant difference between cytokine levels in RA and OA sam-
ples suggest that this should not confound our data.
Here, we report the presence of both the CB1 and CB2 recep-
tors in the synovia of patients with end-stage OA and RA, sug-
gesting that this system may play a role in these pathological
conditions. Our pharmacological study demonstrating that the
potent cannabinoid agonist HU210 phosphorylates ERK1 and
ERK2 in fibroblast-like synovial cells in a PTX-dependent man-
ner via the CB1 receptor lends further support to a functional
role of this receptor system in OA and RA synovia. Although
there was a trend toward an attenuation of the effects of
HU210 by the CB2 receptor antagonist, significance was not
reached. Pre-clinical studies have demonstrated that activa-
tion of CB1 receptors, both on peripheral nerves and at spinal
and supraspinal sites, produces analgesic effects in models of
acute and inflammatory pain [53-55]. By contrast, CB2 recep-
tors are associated predominantly with immune cells (see
Introduction). Although, in the present study, the cellular loca-
tion of the cannabinoid receptors has not been identified, the
demonstration that cannabinoid receptors are coupled to the
MAPK signalling pathway in fibroblast-like cells prepared from
OA and RA synovia indicates that these cells are a likely loca-
tion for the cannabinoid receptors identified.
The two main endocannabinoids, AEA and 2-AG, were
present in the synovia of OA and RA patients at levels in keep-
ing with those previously reported in other biological tissues.
The fatty acid amides PEA and OEA [56] were also detected
in both OA and RA synovia. PEA is of particular interest since
it has anti-inflammatory activity [57] via nuclear PPAR-α (per-
oxisome proliferator activating receptor-α) activation and pos-
sibly endocannabinoid entourage effects. Unfortunately, it was
not possible to obtain non-diseased synovia and, therefore, a
comparison of levels of ECs in normal synovium with OA and
RA samples was not possible. However, we were able to com-
pare levels of endocannabinoids in the synovial fluid, which
contains immune cells that are capable of releasing
endocannabinoids [9], of OA and RA patients compared with
normal volunteers. AEA and 2-AG were present in the synovial
fluid of OA and RA patients, but not in normal controls. Levels
of 2-AG were significantly lower in the RA group compared
with the OA group. Levels of PEA were significantly lower in
the synovial fluid of OA and RA patients compared with that of
non-inflamed normal volunteers. Since PEA has a well-
described anti-inflammatory role, the reported lower levels of
PEA in the synovial fluid of OA and RA patients may contribute
to the disease process associated with these conditions.
Given that AEA, PEA, and OEA are all substrates for FAAH,
the opposing impact of OA/RA on levels of these compounds
suggests that these changes are not due merely to alterations
in FAAH-mediated metabolism and argues against an impor-
tant contribution of the entourage effect. Levels of FAAH activ-
ity were comparable in OA and RA samples. Although activity
of FAAH in the synovium was low relative to the liver, it was
comparable to levels previously described in rat hindpaw [34].
FAAH activity was undetectable in the presence of pharmaco-
logical blockade of FAAH by the well-characterised inhibitor of
URB597 [58], indicating the functional relevance of this activ-
ity. On the basis of our FAAH activity data, changes in rates ofArthritis Research & Therapy    Vol 10 No 2    Richardson et al.
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synthesis or release of AEA and 2-AG, versus PEA and OEA,
in OA and RA patients compared with non-inflamed normal
volunteers are more likely to account for our data.
In some cases, the relative levels of endocannabinoids and
related fatty acid amides in the synovial fluid did not mirror lev-
els in the synovia of OA and RA patients. Levels of 2-AG in the
synovial fluid of RA patients were significantly lower than levels
in OA patients, whereas there were no differences in levels of
2-AG in the synovia of OA and RA patients. In addition, levels
of PEA were non-significantly higher in RA synovium com-
pared with OA synovium, but levels of PEA were similar in the
synovial fluid of OA and RA patients. Thus, levels in the syno-
vial fluid do not simply reflect the level of synthesis/release and
catabolism of endocannabinoids and entourage compounds
in the synovium. The source of the endocannabinoids present
in the synovium and synovial fluid is an important
consideration. Endocannabinoids are synthesised by numer-
ous different cell types, including immune cells such as T cells
and macrophages, which are the major immune cells present
in OA and RA [47,59,60]. Since endothelial cells can synthe-
sise AEA [61] and 2-AG [62], another possible source of
endocannabinoids in the synovium is the vasculature. The role
of vascular elements in the progression of arthritic disease is
important, particularly since neovascularisation is one of the
early changes in the synovium and it is thought that bone and
cartilage destruction is closely linked to angiogenesis [63] and
cannabinoids inhibit angiogenesis in tumours [37,64].
Conclusion
In summary, cannabinoid CB1 and CB2 receptor protein and
RNA and the endocannabinoids AEA and 2-AG are present in
the synovia of patients with end-stage OA and RA. The pres-
ence of increased levels of AEA and 2-AG in the synovial fluid
of OA and RA patients, compared with non-inflamed normal
volunteers, suggests a greater functional role of the endocan-
nabinoid receptor system in these patients. Importantly, levels
of the anti-inflammatory substance PEA were higher in the syn-
ovial fluid of normal volunteers compared with OA and RA
patients and, therefore, the loss of PEA may contribute to
arthritic disease. Our data predict that the cannabinoid recep-
tor system may be an important therapeutic target for the treat-
ment of pain and inflammation associated with these
conditions.
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